COVID-19 Vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Lung CancerLiver TransplantInfluenzaSickle Cell DiseaseInflammatory Bowel DiseaseLong COVID-19Blood Cancer

199 competitors in Lung Cancer

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

322

Imfinzi

AstraZeneca

Phase 3

253

Opdivo

Bristol-Myers Squibb

Phase 3

204

Tagrisso

AstraZeneca

Phase 3

175

Beyfortus

BeiGene

Phase 3

106

Yervoy

Bristol-Myers Squibb

Phase 3

107

Imjudo

AstraZeneca

Phase 3

68

Tecentriq

Roche

Phase 3

69

Alunbrig

Takeda

Phase 3

410

Alecensa

Roche

Phase 3

3Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

COVID-1926 trials

Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

Completed·SSeoul National University Hospital··NCT04910295·112 enrolled

Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination

Completed·Moderna··NCT04941144·8,538 enrolled

Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine

Completed·UUniversità degli Studi dell'Insubria··NCT05083065·369 enrolled

Show 23 more trials

COVID-19 Vaccine Response in Chronic Respiratory Conditions

Unknown status·NNational Jewish Health··NCT05313087·600 enrolled

Immunosuppression and COVID-19 Boosters

Recruiting·KKirby Institute·Phase 3·NCT05415267·320 enrolled

Immunogenicity of COVID-19 Vaccination in PLWH

Unknown status·CCIHR Canadian HIV Trials Network··NCT04894448·500 enrolled

COVID-19 Vaccine Effectiveness in Albanian Health Workers

Unknown status·—··NCT04811391·1,500 enrolled

Host Immune Response to Novel RNA COVID-19 Vaccination

Completed·TThe University of Texas Health Science Center at San Antonio··NCT04784689·50 enrolled

The Impact of Vaccination on Severity of Illness in COVID-19

Completed·CCorewell Health East··NCT04912700·11,834 enrolled

Oral Side Effects of COVID-19 Vaccine

Unknown status·MMasaryk University··NCT04706156·1,540 enrolled

Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium

Unknown status·UUniversiteit Antwerpen··NCT05618548·110 enrolled

Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination

Recruiting·UUniversity of Bergen··NCT04706390·2,500 enrolled

Expectations About the COVID-19 Vaccines

Completed·UUniversity of Aarhus··NCT04928911·1,176 enrolled

Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)

Unknown status·AAlberto Peano··NCT05471635·205 enrolled

Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms

Withdrawn·Takeda··NCT04892888

Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults

Unknown status·—·Phase 4·NCT05012800·300 enrolled

Exercise and COVID-19 Viral T-cell Immunity

Active, not recruiting·UUniversity of Arizona·N/A·NCT05019456·26 enrolled

To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment

Unknown status·UUniversity of Kansas Medical Center··NCT04821570·500 enrolled

Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation

Withdrawn·TThe First Affiliated Hospital of Soochow University··NCT05587881

Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine

Unknown status·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 4·NCT05142488·662 enrolled

Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.

Unknown status·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 4·NCT05157178·1,264 enrolled

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Unknown status·NNational Vaccine and Serum Institute, China·Phase 2·NCT05033847·1,800 enrolled

Plant Stanol Esters and COVID-19 Vaccination Response

Terminated·MMaastricht University Medical Center·N/A·NCT04844346·48 enrolled

Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients

Completed·—··NCT04922944·167 enrolled

Patient-Reported Outcomes Associated With COVID-19 and Influenza: A Prospective Survey Study on Outpatient Symptomatic Adults With Test-Confirmed Illness in the United States

Active, not recruiting·Pfizer··NCT05160636·999 enrolled

COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER)

Completed·PPregistry··NCT04705116·1,184 enrolled

Influenza7 trials

Covid-19 and Influenza Oral Vaccine Study

Recruiting·VVaxine Pty Ltd·Phase 1·NCT06355232·100 enrolled

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

Completed·Moderna·Phase 1/2·NCT05827926·1,758 enrolled

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Completed·Moderna·Phase 2·NCT06864143·1,320 enrolled

Show 4 more trials

Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

Completed·UUniversity of Wisconsin, Madison··NCT05584735·46 enrolled

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.

Withdrawn·Pfizer··NCT06163677

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Completed·BioNTech·Phase 3·NCT06178991·8,795 enrolled

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Completed·Moderna·Phase 3·NCT06097273·8,061 enrolled

Immunogenicity2 trials

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05453487·360 enrolled

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05480436·1,200 enrolled

Rheumatic Disease2 trials

COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases

Unknown status·PPaul R Fortin·Phase 2/3·NCT05236491·287 enrolled

COVID-19 Vaccination in Patients With Rheumatic Diseases

Unknown status·SSociedad Argentina de Reumatologia··NCT04845997·3,000 enrolled

Inflammatory Bowel Disease2 trials

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

Unknown status·GGI Alliance··NCT05014555·400 enrolled

Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases

Unknown status·RRabin Medical Center··NCT05067959·284 enrolled

14 more indications

Hypertension2 trials

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05104333·1,440 enrolled

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05104437·1,440 enrolled

Immune Response1 trial

Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women

Unknown status·SSwiss Federal Institute of Technology·N/A·NCT06116669·180 enrolled

Blood Cancer1 trial

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Active, not recruiting·GGeoVax, Inc.·Phase 2·NCT04977024·63 enrolled

Liver Transplant1 trial

Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation

Unknown status·—··NCT05051605·50 enrolled

Vaccine1 trial

Vaccine Observation to Include All Communities for Equitable Science

Terminated·PPersephone Biosciences··NCT04770649·15 enrolled

Sickle Cell Disease1 trial

COVID-19 Vaccine Response in Sickle Cell Disease

Completed·AASH Research Collaborative··NCT05139992·59 enrolled

Immunity1 trial

Gestational Immunity for Transfer

Unknown status·NNational University Hospital, Singapore··NCT04802278·120 enrolled

Pregnancy1 trial

COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes

Completed·TThomas Jefferson University··NCT04659759·105 enrolled

Long COVID-191 trial

COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients

Unknown status·IIndonesia University··NCT05587868·250 enrolled

Lung Cancer1 trial

Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients

Completed·FFundación GECP··NCT05009030·794 enrolled

Vaccine Response1 trial

Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

Completed·NNicole Stoffel·N/A·NCT05919472·180 enrolled

Immune Deficiency1 trial

Covid-19 Vaccine Cohort in Specific Populations

Completed·AANRS, Emerging Infectious Diseases··NCT04824651·6,922 enrolled

Cardiovascular Diseases1 trial

A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Effect of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women

Completed·QQueen Mary University of London·Phase 1·NCT04889274·42 enrolled

Influenza,Human1 trial

A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS

Completed·BioNTech·Preclinical·NCT06683352·1,353 enrolled

Details

Drug Info

Related News